These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 15210533)
1. Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. Kieseier BC; Archelos JJ; Hartung HP Arch Neurol; 2004 Jun; 61(6):929-32. PubMed ID: 15210533 [TBL] [Abstract][Full Text] [Related]
2. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. Gilli F; Bertolotto A; Sala A; Hoffmann F; Capobianco M; Malucchi S; Glass T; Kappos L; Lindberg RL; Leppert D Brain; 2004 Feb; 127(Pt 2):259-68. PubMed ID: 14607790 [TBL] [Abstract][Full Text] [Related]
3. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients. Bernal F; Elias B; Hartung HP; Kieseier BC Mult Scler; 2009 Jun; 15(6):721-7. PubMed ID: 19383643 [TBL] [Abstract][Full Text] [Related]
4. The effect of interferon beta-1a on MMP-2 and MMP-9 proteolytic activity. Kurzepa J; Stryjecka-Zimmer M Folia Biol (Praha); 2007; 53(6):220-1. PubMed ID: 18070420 [TBL] [Abstract][Full Text] [Related]
5. Effects of IFN-beta, leptin and simvastatin on LIF secretion by T lymphocytes of MS patients and healthy controls. Vanderlocht J; Hendriks JJ; Venken K; Stinissen P; Hellings N J Neuroimmunol; 2006 Aug; 177(1-2):189-200. PubMed ID: 16797728 [TBL] [Abstract][Full Text] [Related]
6. Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis. Yushchenko M; Mäder M; Elitok E; Bitsch A; Dressel A; Tumani H; Bogumil T; Kitze B; Poser S; Weber F J Neurol; 2003 Oct; 250(10):1224-8. PubMed ID: 14586607 [TBL] [Abstract][Full Text] [Related]
11. Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate. Neuhaus O; Stüve O; Archelos JJ; Hartung HP J Neurol Sci; 2005 Jun; 233(1-2):173-7. PubMed ID: 15949504 [TBL] [Abstract][Full Text] [Related]
12. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial. Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the immunomodulatory effects of the plant sterol beta-sitosterol to simvastatin in peripheral blood cells from multiple sclerosis patients. Desai F; Ramanathan M; Fink CS; Wilding GE; Weinstock-Guttman B; Awad AB Int Immunopharmacol; 2009 Jan; 9(1):153-7. PubMed ID: 19022404 [TBL] [Abstract][Full Text] [Related]
14. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Byun E; Caillier SJ; Montalban X; Villoslada P; Fernández O; Brassat D; Comabella M; Wang J; Barcellos LF; Baranzini SE; Oksenberg JR Arch Neurol; 2008 Mar; 65(3):337-44. PubMed ID: 18195134 [TBL] [Abstract][Full Text] [Related]
15. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Biernacki K; Antel JP; Blain M; Narayanan S; Arnold DL; Prat A Arch Neurol; 2005 Apr; 62(4):563-8. PubMed ID: 15824253 [TBL] [Abstract][Full Text] [Related]
16. Simvastatin reduces MMP-3 level in interleukin 1beta stimulated human chondrocyte culture. Lazzerini PE; Capecchi PL; Nerucci F; Fioravanti A; Chellini F; Piccini M; Bisogno S; Marcolongo R; Laghi Pasini F Ann Rheum Dis; 2004 Jul; 63(7):867-9. PubMed ID: 15194586 [TBL] [Abstract][Full Text] [Related]
17. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209 [TBL] [Abstract][Full Text] [Related]
18. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Comabella M; Río J; Espejo C; Ruiz de Villa M; Al-Zayat H; Nos C; Deisenhammer F; Baranzini SE; Nonell L; López C; Julià E; Oksenberg JR; Montalban X Clin Immunol; 2009 Feb; 130(2):145-50. PubMed ID: 18945642 [TBL] [Abstract][Full Text] [Related]
19. Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. Yong VW; Zabad RK; Agrawal S; Goncalves Dasilva A; Metz LM J Neurol Sci; 2007 Aug; 259(1-2):79-84. PubMed ID: 17382965 [TBL] [Abstract][Full Text] [Related]